University of Dundee First to Install Biacore 4000 SPR System
News Jun 16, 2010
The University of Dundee announced that it has become the first facility worldwide to take delivery of Biacore™ 4000. Biacore 4000 is a solution for large-scale, label-free molecular interaction analysis in drug discovery, from early screening to characterization.
The University of Dundee and spin-out company Kinetic Discovery Ltd will be using the system to focus on developing biophysical fragment based screening methodologies for efficient drug discovery.
Dr Iva Navratilova, Independent Investigator, University of Dundee and founder of Kinetic Discovery, commented: “We are developing biosensor based screening methods that enable us to characterize the kinetics and thermodynamics of molecular interactions. The unprecedented combination of high sample capacity and sensitivity provided by Biacore 4000 means we can now carry out highly accurate screening of our fragment library in only a couple of days, rather than the weeks it would have otherwise taken.”
Dr. Navratilova also plans to use Biacore 4000 to continue her work on developing biosensor SPR methods for screening native membrane proteins such as GPCRs, an important class of drug targets. SPR is used to characterize complex kinetic interactions of GPCRs with their natural ligands or low molecular weight inhibitors. The system is designed for large-scale parallel interaction analyses, with the capability to analyze up to 4800 interactions in 24hrs, ideal for running biophysical screening campaigns on selected compound libraries.
Structural methods used for fragment screening present several technical challenges, including consumption of large amounts of target protein, and a requirement for high sample concentrations due to the low (typically micromolar to millimolar) affinities exhibited by fragments, which leads to solubility/non-specific binding issues. SPR-based strategies can be designed to overcome many of these issues, providing an efficient, informative complement to structural methods. The kinetic information obtained can then be used to support further compound optimization efforts.
“We’re very excited to be the first facility to install a Biacore 4000 instrument”, said Prof. Andrew Hopkins, Chair of Medicinal Informatics and SULSA Research Professor of Translational Biology, University of Dundee, and CEO of Kinetic Discovery: “We believe this reinforces our position as a world leader in the field of SPR based fragment screening, and we look forward to seeing the many benefits the purchase will make to our research efforts.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017